Acute Myeloid Leukemia Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Novartis AG, Genmab AS, Sanofi, Teva Pharma, Pfizer, F. Hoffmann-La Roche Ltd, Sunesis Pharma, Bristol-Myers Squibb Company, Otsuka Holdings

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Myeloid Leukemia pipeline constitutes 110+ key companies continuously working towards developing 120+ Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acute Myeloid Leukemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Myeloid Leukemia Market.

Some of the key takeaways from the Acute Myeloid Leukemia Pipeline Report: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years.
• Acute Myeloid Leukemia companies working in the treatment market are SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others, are developing therapies for the Acute Myeloid Leukemia treatment
• Emerging Acute Myeloid Leukemia therapies in the different phases of clinical trials are- GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, and others are expected to have a significant impact on the Acute Myeloid Leukemia market in the coming years.
• In May 2024, GlycoMimetics, a biotechnology company based in the United States, has unveiled the key findings from its Phase III clinical trial of uproleselan, an E-selectin antagonist developed for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). The randomized, double-blind, placebo-controlled trial evaluated uproleselan in combination with either mitoxantrone, etoposide, and cytarabine (MEC) or fludarabine, cytarabine, and idarubicin (FAI) chemotherapy regimens. Patients were administered either uproleselan or a placebo during one cycle of induction and up to three cycles of consolidation, if applicable.
• In August 2023, Gilead Sciences revealed that the US Food and Drug Administration (FDA) has decided to temporarily halt the screening and enrollment of patients in US-based studies examining the treatment of acute myeloid leukemia (AML) using magrolimab. This partial clinical hold comes in the wake of the termination of a Phase III trial exploring the combination of the same drug with azacitidine in patients diagnosed with higher-risk myelodysplastic syndromes (MDS). Gilead opted to discontinue the study due to unsatisfactory efficacy outcomes, rather than safety issues.

Acute Myeloid Leukemia Overview
Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It originates in the myeloid line of blood cells, which are responsible for producing red blood cells, platelets, and certain types of white blood cells (granulocytes and monocytes).

Get a Free Sample PDF Report to know more about Acute Myeloid Leukemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:
• GNC 035: SystImmune
• JSP 191: Jasper Therapeutics
• ONC201: Chimerix
• AK117: Akeso Biopharma Co., Ltd.
• Tamibarotene: Syros Pharmaceuticals
• TCB008: TC Biopharm
• Elzonris: Stemline Therapeutics
• Orca T: Orca Bio
• Magrolimab+ azacitidine: Gilead Sciences
• Uproleselan: GlycoMimetics

Acute Myeloid Leukemia Route of Administration
Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Myeloid Leukemia Molecule Type
Acute Myeloid Leukemia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Acute Myeloid Leukemia Pipeline Therapeutics Assessment
• Acute Myeloid Leukemia Assessment by Product Type
• Acute Myeloid Leukemia By Stage and Product Type
• Acute Myeloid Leukemia Assessment by Route of Administration
• Acute Myeloid Leukemia By Stage and Route of Administration
• Acute Myeloid Leukemia Assessment by Molecule Type
• Acute Myeloid Leukemia by Stage and Molecule Type

DelveInsight's Acute Myeloid Leukemia Report covers around 120+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Myeloid Leukemia product details are provided in the report. Download the Acute Myeloid Leukemia pipeline report to learn more about the emerging Acute Myeloid Leukemia therapies
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Acute Myeloid Leukemia Therapeutics Market include:
Key companies developing therapies for Acute Myeloid Leukemia are - GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics Inc, Cullinan Therapeutics Inc, Aptose Biosciences Inc, Celgene, and others.

Acute Myeloid Leukemia Pipeline Analysis:
The Acute Myeloid Leukemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
• Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Myeloid Leukemia drugs and therapies
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Myeloid Leukemia Pipeline Market Drivers
• Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Acute Myeloid Leukemia Market.

Acute Myeloid Leukemia Pipeline Market Barriers
• However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Acute Myeloid Leukemia Market growth.

Scope of Acute Myeloid Leukemia Pipeline Drug Insight
• Coverage: Global
• Key Acute Myeloid Leukemia Companies: SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others
• Key Acute Myeloid Leukemia Therapies: GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, and others
• Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers

Request for Sample PDF Report for Acute Myeloid Leukemia Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acute Myeloid Leukemia Report Introduction
2. Acute Myeloid Leukemia Executive Summary
3. Acute Myeloid Leukemia Overview
4. Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment
5. Acute Myeloid Leukemia Pipeline Therapeutics
6. Acute Myeloid Leukemia Late Stage Products (Phase II/III)
7. Acute Myeloid Leukemia Mid Stage Products (Phase II)
8. Acute Myeloid Leukemia Early Stage Products (Phase I)
9. Acute Myeloid Leukemia Preclinical Stage Products
10. Acute Myeloid Leukemia Therapeutics Assessment
11. Acute Myeloid Leukemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acute Myeloid Leukemia Key Companies
14. Acute Myeloid Leukemia Key Products
15. Acute Myeloid Leukemia Unmet Needs
16 . Acute Myeloid Leukemia Market Drivers and Barriers
17. Acute Myeloid Leukemia Future Perspectives and Conclusion
18. Acute Myeloid Leukemia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Acute Myeloid Leukemia Market https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Myeloid Leukemia Epidemiology https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Myeloid Leukemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.

Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others

Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.